How to take venetoclax for myeloid leukemia

Before starting venetoclax therapy, patients should undergo a comprehensive physical examination, especially liver and kidney function and routine blood tests. The doctor will develop a personalized treatment plan based on the patient's specific situation.

For newly diagnosed patients with acute myeloid leukemia, especially adults 75 years of age and older or patients with comorbidities, there are specific dosage regimens for venetoclax. A combination of azacitidine, decitabine, or low-dose cytarabine is usually initiated on day 1. The initial dose of venetoclax is 100 mg once daily, increasing to daily on day 2 pan>200mg, on day 3 once a day400mg. Thereafter, if combined with azacitidine or decitabine, 400 mg daily starting on day 4 until disease progression or unacceptable toxicity. If combined with low-dose cytarabine, take 600mg daily starting from the 4th day.

For patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, the dose of venetoclax is started in a stepwise increase over 5 weeks. Specifically: 1week 20mg per day 2week 50mg per day 3week< /span>100mg per day for week 4200mg per day for week 5 and thereafter 400mg per day.

Patients should take venetoclax tablets with a meal and water at approximately the same time each day to ensure a steady release of the drug in the body. Venetoclax should be taken with food to increase absorption. A treatment cycle is usually 28days, the specific number of cycles depends on the patient’s condition and doctor’s recommendations.

Patients should closely monitor blood cell counts and liver and kidney function while taking venetoclax.

If serious side effects or unacceptable toxicity occur, seek medical attention immediately and may need to adjust the drug dose or suspend treatment.

Patients should avoid becoming pregnant while taking venetoclax because of the potential for harm to the fetus.